+

WO2011093810A3 - Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone - Google Patents

Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone Download PDF

Info

Publication number
WO2011093810A3
WO2011093810A3 PCT/TR2011/000012 TR2011000012W WO2011093810A3 WO 2011093810 A3 WO2011093810 A3 WO 2011093810A3 TR 2011000012 W TR2011000012 W TR 2011000012W WO 2011093810 A3 WO2011093810 A3 WO 2011093810A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
dry powder
mometasone
pharmaceutical composition
powder pharmaceutical
Prior art date
Application number
PCT/TR2011/000012
Other languages
English (en)
Other versions
WO2011093810A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00619A external-priority patent/TR201000619A2/xx
Priority claimed from TR2010/00730A external-priority patent/TR201000730A2/xx
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093810A2 publication Critical patent/WO2011093810A2/fr
Publication of WO2011093810A3 publication Critical patent/WO2011093810A3/fr
Priority to US13/531,972 priority Critical patent/US8834931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques sous forme de poudre sèche comprenant du tiotropium et du furoate de mométasone et/ou leurs dérivés acceptables au plan pharmaceutique en tant que principes actifs, ainsi que des formes de capsules et d'emballage-coques contenant ces compositions pharmaceutiques afin d'être utilisées dans le traitement de maladies des voies respiratoires.
PCT/TR2011/000012 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone WO2011093810A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00619A TR201000619A2 (tr) 2010-01-28 2010-01-28 Tiotropium ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.
TR2010/00619 2010-01-28
TR2010/00730 2010-02-02
TR2010/00730A TR201000730A2 (tr) 2010-02-02 2010-02-02 Tiotropyum ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000014 Continuation-In-Part WO2011093812A2 (fr) 2009-12-25 2011-01-28 Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000011 Continuation-In-Part WO2011093809A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide

Publications (2)

Publication Number Publication Date
WO2011093810A2 WO2011093810A2 (fr) 2011-08-04
WO2011093810A3 true WO2011093810A3 (fr) 2012-02-23

Family

ID=43899579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 WO2011093810A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone

Country Status (1)

Country Link
WO (1) WO2011093810A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078743A1 (fr) * 2000-04-18 2001-10-25 Glaxo Group Limited Produits composes a usage medical renfermant du tiotropium et de la mometasone
US20050123486A1 (en) * 2003-12-03 2005-06-09 Microdrug Ag Medical product containing tiotropium
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2011078817A1 (fr) * 2009-12-25 2011-06-30 Mahmut Bilgic Poudre séche combinant tiotropium, mométasone et un dérivé d'acide cromoglicique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
TR200803523A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Şerit ambalaj içeren düzenek
TR200803522A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078743A1 (fr) * 2000-04-18 2001-10-25 Glaxo Group Limited Produits composes a usage medical renfermant du tiotropium et de la mometasone
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US20050123486A1 (en) * 2003-12-03 2005-06-09 Microdrug Ag Medical product containing tiotropium
WO2011078817A1 (fr) * 2009-12-25 2011-06-30 Mahmut Bilgic Poudre séche combinant tiotropium, mométasone et un dérivé d'acide cromoglicique

Also Published As

Publication number Publication date
WO2011093810A2 (fr) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
WO2013183062A3 (fr) Formulations d'ibuprofène de goût agréable
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
WO2014016548A3 (fr) Composition pharmaceutique
PH12012502085A1 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2011093815A3 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
WO2010042701A3 (fr) Compositions à base de corticoïdes et procédés de traitement associés
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2011101734A3 (fr) Poudre à goût masqué pour compositions en suspension de méthylprednisolone
WO2011093811A3 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
WO2011093812A3 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2012030308A3 (fr) Formulation comprenant la cellobiose
WO2011093814A3 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
EP2583966A4 (fr) Dérivé de rgd cyclique marqué par du tricarbonyl-technétium-99m ou -rhénium-188, son procédé de préparation et composition pharmaceutique contenant le dérivé comme principe actif destinée à être utilisée dans le diagnostic ou le traitement de maladies liées à l'angiogenèse
WO2011093810A3 (fr) Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone
WO2012007758A3 (fr) Formulations pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11707730

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11707730

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载